TJC-0265 is under clinical development by TaiwanJ Pharmaceuticals and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TJC-0265’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TJC-0265 overview

TJC-0265 is under development for the treatment of non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). It acts by targeting autotaxin. The drug candidate is a new chemical entity (NCE).

TaiwanJ Pharmaceuticals overview

TaiwanJ Pharmaceuticals (TaiwanJ) is a pharmaceutical company. It develops and commercializes small molecules for unmet medical needs such as chronic organ inflammation of metabolic, autoimmune and infectious etiologies. The company develops TLR4, a transmembrane protein that acts as a key mediator of inflammatory responses. TaiwanJ’s pipeline products include JKB-122, TJC0265, TJC0434, TJC0545, TJC0667, and other products. The company offers drugs to lower clinical risks and minimizes the cost of development by re-profiling approved drugs. Its target therapy areas include chronic liver disease, kidney injury, inflammatory bowel disease, rheumatoid arthritis, liver inflammation, liver fibrosis, NASH and Crohn’s Disease. The company works in collaboration with pharmaceutical companies and institutes for its product development. TaiwanJ is headquartered in Zhubei City, Taiwan.

For a complete picture of TJC-0265’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.